@article{thrush_multi-institutional_nodate,
	title = {A multi-institutional evaluation of antibody-mediated rejection utilizing the {Pediatric} {Heart} {Transplant} {Study} database: {Incidence}, therapies and outcomes.},
	volume = {35},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27431753},
	doi = {10.1016/j.healun.2016.06.014},
	abstract = {BACKGROUND: Current knowledge of antibody-mediated rejection (AMR) after heart transplantation (HT) stems largely from adult data. Using the Pediatric Heart Transplant Study (PHTS) database, we report the incidence of AMR, describe treatment, and evaluate outcomes for treated AMR in children after HT. METHODS: We queried the PHTS database for patients {\textless}18 years of age undergoing primary HT between January 2010 and December 2014. An AMR episode was defined as either a biopsy consistent with pathologic AMR or a rejection event based on immunotherapy augmentation directed against antibody production. Biopsy data, treatment strategies and survival were analyzed. RESULTS: An episode of AMR was identified in 179 of 1,596 (11\%) HT recipients and in 246 of 705 (35\%) rejection episodes. AMR was diagnosed by biopsy in 182 of 246 episodes and by immunotherapy in 64 of 179 episodes. Mixed rejection was identified in 179. Freedom from AMR was 88\% and 82\% at 1 and 3 years, respectively. AMR therapies included intravenous immunoglobulin (IVIg) (58\%), plasmapheresis (40\%), rituximab (40\%), bortezomib (11\%) and eculizumab (0.4\%). The most commonly used combination therapies included IVIg/plasmapheresis/rituximab (13\%). Thirty-three patients (16\%) died after developing AMR. Patient and graft survival were lower for the AMR+ group. One- and 3-year survival after initial AMR diagnosis was 88\% and 77\%, respectively. CONCLUSIONS: In his study we report the largest experience of AMR in pediatric HT recipients. AMR was common and often occurred concurrently with acute cellular rejection. There is wide variability in the treatment of AMR. Short-term patient and graft outcomes were worse for those with treated AMR.},
	language = {eng},
	number = {12},
	journal = {J Heart Lung Transplant},
	author = {Thrush, PT and Pahl, E and Naftel, DC and Pruitt, E and Everitt, MD and Missler, H and Zangwill, S and Burch, M and Hoffman, TM and Butts, R and Mahle, WT},
	keywords = {Retrospective Studies},
	pages = {1497--1504}
}

{"_id":"uainXeBQhbAAdg54f","bibbaseid":"thrush-pahl-naftel-pruitt-everitt-missler-zangwill-burch-etal-amultiinstitutionalevaluationofantibodymediatedrejectionutilizingthepediatrichearttransplantstudydatabaseincidencetherapiesandoutcomes","downloads":0,"creationDate":"2019-02-06T19:19:41.808Z","title":"A multi-institutional evaluation of antibody-mediated rejection utilizing the Pediatric Heart Transplant Study database: Incidence, therapies and outcomes.","author_short":["Thrush, P.","Pahl, E","Naftel, D.","Pruitt, E","Everitt, M.","Missler, H","Zangwill, S","Burch, M","Hoffman, T.","Butts, R","Mahle, W."],"year":null,"bibtype":"article","biburl":"https://api.zotero.org/users/5494130/collections/TR8UM4WJ/items?key=bPKCKbQJ3ej3KoeUhSSlR8nj&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"A multi-institutional evaluation of antibody-mediated rejection utilizing the Pediatric Heart Transplant Study database: Incidence, therapies and outcomes.","volume":"35","url":"https://www.ncbi.nlm.nih.gov/pubmed/27431753","doi":"10.1016/j.healun.2016.06.014","abstract":"BACKGROUND: Current knowledge of antibody-mediated rejection (AMR) after heart transplantation (HT) stems largely from adult data. Using the Pediatric Heart Transplant Study (PHTS) database, we report the incidence of AMR, describe treatment, and evaluate outcomes for treated AMR in children after HT. METHODS: We queried the PHTS database for patients \\textless18 years of age undergoing primary HT between January 2010 and December 2014. An AMR episode was defined as either a biopsy consistent with pathologic AMR or a rejection event based on immunotherapy augmentation directed against antibody production. Biopsy data, treatment strategies and survival were analyzed. RESULTS: An episode of AMR was identified in 179 of 1,596 (11%) HT recipients and in 246 of 705 (35%) rejection episodes. AMR was diagnosed by biopsy in 182 of 246 episodes and by immunotherapy in 64 of 179 episodes. Mixed rejection was identified in 179. Freedom from AMR was 88% and 82% at 1 and 3 years, respectively. AMR therapies included intravenous immunoglobulin (IVIg) (58%), plasmapheresis (40%), rituximab (40%), bortezomib (11%) and eculizumab (0.4%). The most commonly used combination therapies included IVIg/plasmapheresis/rituximab (13%). Thirty-three patients (16%) died after developing AMR. Patient and graft survival were lower for the AMR+ group. One- and 3-year survival after initial AMR diagnosis was 88% and 77%, respectively. CONCLUSIONS: In his study we report the largest experience of AMR in pediatric HT recipients. AMR was common and often occurred concurrently with acute cellular rejection. There is wide variability in the treatment of AMR. Short-term patient and graft outcomes were worse for those with treated AMR.","language":"eng","number":"12","journal":"J Heart Lung Transplant","author":[{"propositions":[],"lastnames":["Thrush"],"firstnames":["PT"],"suffixes":[]},{"propositions":[],"lastnames":["Pahl"],"firstnames":["E"],"suffixes":[]},{"propositions":[],"lastnames":["Naftel"],"firstnames":["DC"],"suffixes":[]},{"propositions":[],"lastnames":["Pruitt"],"firstnames":["E"],"suffixes":[]},{"propositions":[],"lastnames":["Everitt"],"firstnames":["MD"],"suffixes":[]},{"propositions":[],"lastnames":["Missler"],"firstnames":["H"],"suffixes":[]},{"propositions":[],"lastnames":["Zangwill"],"firstnames":["S"],"suffixes":[]},{"propositions":[],"lastnames":["Burch"],"firstnames":["M"],"suffixes":[]},{"propositions":[],"lastnames":["Hoffman"],"firstnames":["TM"],"suffixes":[]},{"propositions":[],"lastnames":["Butts"],"firstnames":["R"],"suffixes":[]},{"propositions":[],"lastnames":["Mahle"],"firstnames":["WT"],"suffixes":[]}],"keywords":"Retrospective Studies","pages":"1497–1504","bibtex":"@article{thrush_multi-institutional_nodate,\n\ttitle = {A multi-institutional evaluation of antibody-mediated rejection utilizing the {Pediatric} {Heart} {Transplant} {Study} database: {Incidence}, therapies and outcomes.},\n\tvolume = {35},\n\turl = {https://www.ncbi.nlm.nih.gov/pubmed/27431753},\n\tdoi = {10.1016/j.healun.2016.06.014},\n\tabstract = {BACKGROUND: Current knowledge of antibody-mediated rejection (AMR) after heart transplantation (HT) stems largely from adult data. Using the Pediatric Heart Transplant Study (PHTS) database, we report the incidence of AMR, describe treatment, and evaluate outcomes for treated AMR in children after HT. METHODS: We queried the PHTS database for patients {\\textless}18 years of age undergoing primary HT between January 2010 and December 2014. An AMR episode was defined as either a biopsy consistent with pathologic AMR or a rejection event based on immunotherapy augmentation directed against antibody production. Biopsy data, treatment strategies and survival were analyzed. RESULTS: An episode of AMR was identified in 179 of 1,596 (11\\%) HT recipients and in 246 of 705 (35\\%) rejection episodes. AMR was diagnosed by biopsy in 182 of 246 episodes and by immunotherapy in 64 of 179 episodes. Mixed rejection was identified in 179. Freedom from AMR was 88\\% and 82\\% at 1 and 3 years, respectively. AMR therapies included intravenous immunoglobulin (IVIg) (58\\%), plasmapheresis (40\\%), rituximab (40\\%), bortezomib (11\\%) and eculizumab (0.4\\%). The most commonly used combination therapies included IVIg/plasmapheresis/rituximab (13\\%). Thirty-three patients (16\\%) died after developing AMR. Patient and graft survival were lower for the AMR+ group. One- and 3-year survival after initial AMR diagnosis was 88\\% and 77\\%, respectively. CONCLUSIONS: In his study we report the largest experience of AMR in pediatric HT recipients. AMR was common and often occurred concurrently with acute cellular rejection. There is wide variability in the treatment of AMR. Short-term patient and graft outcomes were worse for those with treated AMR.},\n\tlanguage = {eng},\n\tnumber = {12},\n\tjournal = {J Heart Lung Transplant},\n\tauthor = {Thrush, PT and Pahl, E and Naftel, DC and Pruitt, E and Everitt, MD and Missler, H and Zangwill, S and Burch, M and Hoffman, TM and Butts, R and Mahle, WT},\n\tkeywords = {Retrospective Studies},\n\tpages = {1497--1504}\n}\n\n","author_short":["Thrush, P.","Pahl, E","Naftel, D.","Pruitt, E","Everitt, M.","Missler, H","Zangwill, S","Burch, M","Hoffman, T.","Butts, R","Mahle, W."],"key":"thrush_multi-institutional_nodate","id":"thrush_multi-institutional_nodate","bibbaseid":"thrush-pahl-naftel-pruitt-everitt-missler-zangwill-burch-etal-amultiinstitutionalevaluationofantibodymediatedrejectionutilizingthepediatrichearttransplantstudydatabaseincidencetherapiesandoutcomes","role":"author","urls":{"Paper":"https://www.ncbi.nlm.nih.gov/pubmed/27431753"},"keyword":["Retrospective Studies"],"downloads":0,"html":""},"search_terms":["multi","institutional","evaluation","antibody","mediated","rejection","utilizing","pediatric","heart","transplant","study","database","incidence","therapies","outcomes","thrush","pahl","naftel","pruitt","everitt","missler","zangwill","burch","hoffman","butts","mahle"],"keywords":["retrospective studies"],"authorIDs":[],"dataSources":["D3kJ3SDyHJDJHj4gQ"]}